5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy

Boileve, A; Wicker, C; Verret, B; Leroy, F; Malka, D; Jozwiake, M; Pontoizeau, C; Ottolenghi, C; De Lonlay, P; Ducreux, M; Hollebecque, A

Boileve, A (reprint author), Gustave Roussy Hosp, Med Oncol Dept, 114 Rue Edouard Vaillant, F-94800 Villejuif, France.

ANTI-CANCER DRUGS, 2019; 30 (3): 313

Abstract

For several decades, 5-Fluorouracil (5-FU) has been the backbone of many chemotherapy regimens for various tumor types. Its most common side effects a......

Full Text Link